Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

07/29/2021 | 07:03am EDT

Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.

Incorporated by reference is a press release issued by Merck & Co., Inc. on July 29, 2021, regarding earnings for the second quarter of 2021, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.

This information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



 (d) Exhibits




                   Press release issued July 29, 2021, regarding earnings for the
  Exhibit 99.1   second quarter of 2021

                   Certain supplemental information not included in the press
  Exhibit 99.2   release

                 Cover Page Interactive Data File (embedded within the Inline XBRL
  Exhibit 104    document)

© Edgar Online, source Glimpses

All news about MERCK & CO., INC.
09/27MERCK : Said to Buy Acceleron Pharma in Rare Diseases Boost
MT
09/27MERCK : Announces KEYTRUDA« (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) ..
BU
09/27MERCK : Says Keytruda Met Primary Endpoint of Overall Survival in Patients With Liver Canc..
MT
09/27MERCK : LYNPARZA (olaparib) in combination with abiraterone significantly delayed disease ..
AQ
09/27MERCK : LYNPARZA (olaparib) in Combination With Abiraterone Significantly Delayed Disease ..
AQ
09/27Merck Says Keytruda Liver Cancer Study Meets Objective
DJ
09/24Health Care Stocks Retreat Friday
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
09/24MERCK : LYNPARZA« (olaparib) in Combination With Abiraterone Significantly Delayed Disease..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 16,0x
Yield 2021 3,53%
Capitalization 186 B 186 B -
EV / Sales 2021 4,29x
EV / Sales 2022 3,88x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,36 $
Average target price 93,42 $
Spread / Average Target 27,3%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.32%185 702
JOHNSON & JOHNSON3.68%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.19.37%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY34.09%205 250